FRE.DE Fresenius SE & Co. KGaA (XETRA) pre-market 20 Feb 2026: earnings due Feb 25 could drive price

Fresenius SE & Co. KGaA (FRE.DE) trades at €52.08 pre-market on XETRA on 20 Feb 2026, with earnings due on 25 Feb 2026. Traders view the report as the main near-term catalyst for the stock. Our earnings spotlight covers price drivers, valuation, technical setup, and consensus risks. We use company metrics and sector context to set expectations for possible moves into the print.

Earnings outlook and near-term catalysts for FRE.DE stock

Fresenius announces results on 25 Feb 2026 and investors will watch revenue, margins and guidance. Consensus sensitivity centers on Fresenius Medical Care volumes, Fresenius Kabi margins and Helios hospital occupancy. One clear catalyst is any change to 2026 guidance or margin commentary. A better-than-expected EPS beat could lift the stock above the €52.96 year high; weak guidance could test the €51.72 intraday support.

Recent price action, volume and technicals for FRE.DE stock

Price closed pre-market at €52.08 on low relative volume of 591,538 shares versus average 674,417. Momentum indicators show strength: RSI 65.35, MACD histogram 0.31, and Stochastic %K 94.31 suggesting short-term overbought conditions. The 50-day average €48.81 and 200-day average €46.22 both sit below the current price, signalling a bullish moving-average trend. Traders should note an ATR of 1.01 for intraday range expectations.

Fundamentals and valuation: what the numbers say about FRE.DE stock

Fresenius shows trailing EPS €2.05 and a PE of 25.40 on the current price. Market cap is €29,333,397,386.00 and price-to-sales sits near 1.31. Return on equity is 6.03%, debt-to-equity 0.73, and interest coverage about 6.34, indicating moderate leverage and acceptable coverage. Free cash flow yield is roughly 4.12%, while dividend per share is €1.00, yielding about 1.92%.

Meyka AI grade, forecast and scenario analysis for FRE.DE stock

Meyka AI rates FRE.DE with a score out of 100: 69.89 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of €60.96, implying an upside of +17.06% versus the current €52.08. Forecasts are model-based projections and not guarantees.

Risks, opportunities and sector context for FRE.DE stock

Key risks include operational exposure in dialysis services, regulatory reimbursement shifts, and slower demand in hospital services. Opportunities include margin recovery at Fresenius Kabi, service expansion in Helios, and cost controls. In the Healthcare sector on German markets, peers trade at an average PE near 30.92; Fresenius’s PE 25.40 leaves room for re-rating if growth and cash flow stabilise.

What to watch into the earnings print for FRE.DE stock

Watch these data points on 25 Feb 2026: organic revenue growth, margin guidance by segment, cash flow trends, and capital allocation comments. Monitor management language on pricing and reimbursement. Also check hospital occupancy trends for Helios and dialysis utilization for Fresenius Medical Care. Use volatility (MFI 76.38) to size positions around the print.

Final Thoughts

Key takeaways for FRE.DE stock ahead of earnings: the stock trades pre-market at €52.08 on XETRA in Germany and faces an important earnings report on 25 Feb 2026 that can change near-term direction. Valuation is moderate with PE 25.40 and free cash flow yield around 4.12%. Technicals show momentum but short-term overbought signals; average volume is slightly below normal at 591,538. Meyka AI’s forecast model projects a yearly price of €60.96, implying a +17.06% upside versus the current level; monthly and quarterly model points are €51.10 and €55.38, implying short-term downside -1.88% and upside +6.34% respectively. Forecasts are model-based projections and not guarantees. Use the earnings release and management guidance to reassess risk-reward, and size positions to reflect volatility and event risk. Meyka AI provides this analysis as an AI-powered market analysis platform, not as investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.